INDIA – Dr. Reddy’s Laboratories Ltd. has acquired the domestic sale rights for breast cancer drug PRIMCYV® from Pfizer Products India Pvt Ltd.

The trademark rights acquisition will build on Dr. Reddy’s collaboration with Pfizer for the marketing of its drug under the brand name PRIMCYV® in India.

According to the company’s press statement, PRIMCYV® is a targeted therapy containing the active constituent Palbociclib, a first CDK4/6 inhibitor to be approved as a cancer therapy.

Dr. Reddy’s is amongst select companies in the world to have conducted a bioequivalence study and received tentative approval from the United States Food and Drug Administration (USFDA) for Palbociclib,” the pharma giant announced.

The drug maker pointed out that the first-in-class inhibitor indicated in combination with an aromatase inhibitor for the first-line treatment of adult patients with HR+, HER2- metastatic breast cancer.

The in-house product will be retailed in the Indian market at a reduction of 85% from the current MRP to increase affordability and access to Palbociclib,” the Indian pharmaceutical company said.

Following the trademark rights acquisition, Dr. Reddy’s will manufacture the Active Pharmaceutical Ingredient (API) and finished drug at its USFDA-approved facilities.

The company further disclosed that it has plans to roll out a unique Patient Assistance Programme to support long-term therapy of the patients on Pfizer’s breast cancer drug in the Indian market.

Dr. Reddy’s highlighted that the cancer drug will be available in the form of hard capsules in strengths of 75 mg, 100 mg and 125 mg.

Through leading brands such as Hervycta, Mitotax, Docetere, Nab Mitotax, Primcyv, and others, Dr. Reddy’s has made a portfolio of reliable and high-quality medicines available to patients in India in keeping with its purpose of ‘Good Health Can’t Wait,” the company underscored.

Meanwhile, Dr. Reddy’s and Theranica, a prescribed digital therapeutics company in Israel, have entered into a strategic licensing pact for the exclusive marketing and distribution of Nerivio® that will be used to treat chronic pain in India.

Nerivio is the first FDA-cleared, prescribed, digitally connected, drug-free wearable device for the acute treatment of episodic and chronic migraine in individuals age 12 and older.

The Indian drug major will be responsible for the regulatory approval of Nerivio in India, after which it will exclusively market Nerivio in India as standard of care pharmacological option for acute migraine treatment.

Upon completion of the regulatory approval process, Theranica and Dr. Reddy’s will work together to ensure Nerivio is accessible to millions of people who suffer from this debilitating neurological disorder.

For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.